NCT/Study#
NCT04989803 /
KT-US-499-0150-01
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
